Consensus Recommendations for Diagnosis and Management of Vanishing White Matter - Part 2
Release Date: 03/02/2026
TRPM8 Antagonism with Elismetrep: A Novel Approach for Treating Migraine - Part 1
Neurology Minute
In part one of this series, Dr. Tesha Monteith and Dr. Brett Lauring discuss the potential role TRPM8 antagonist may play in the management of migraine. Read more about this abstract on the .
info_outline
FDA Revises Trial Requirements for Drug and Medical Product Approval - Part 2
Neurology Minute
In part two of this series, Dr. Justin Abbatemarco and Lizzy Lawrence discuss recent FDA guidance, focusing on broader agency changes and how this messaging differs from the FDA’s traditional communication around regulatory decision-making. Show citation:
info_outline
April 2026 President Spotlight: Supporting Neurology in Every Practice Setting
Neurology Minute
In the March episode of the President's Spotlight, Dr. Jason Crowell and Dr. Natalia Rost discuss some of the most pressing challenges facing academic neurology while supporting neurologists in all practice settings. Stay informed by watching the video.
info_outline
Antiseizure Medication Dosing Strategy During Pregnancy and Early Postpartum in Women With Epilepsy in MONEAD
Neurology Minute
Dr. Derek Stitt and Dr. Page B. Pennell discuss antiseizure medication management during pregnancy and postpartum, based on the MONEAD study. Show citation: Pennell PB, Li D, Kerr WT, et al. Antiseizure Medication Dosing Strategy During Pregnancy and Early Postpartum in Women With Epilepsy in MONEAD. Neurology. 2026;106(2):e214483. doi:
info_outline
FDA Revises Trial Requirements for Drug and Medical Product Approval - Part 1
Neurology Minute
In part one of this series, Dr. Justin Abbatemarco and Lizzy Lawrence discuss the FDA’s shift toward single-trial drug approvals. Show citation:
info_outline
Real-World Implementation of an AI Clinical Assistant in Neurology
Neurology Minute
Dr. Halley Alexander and Dr. Mikael Guzman Karlsson discuss the development and evaluation of an AI-enabled clinical assistant designed to support time-sensitive decision-making in neurology. View the related abstract:
info_outline
A Roadmap to Neurological Health Equity - Part 2
Neurology Minute
In part two of this series, Dr. Tesha Monteith and Dr. Nimish A. Mohile discuss the motivation behind the development of this roadmap to neurological health equity. Show citation: Patel PB, Hamilton RH, Budhu JA, et al. A Roadmap to Neurologic Health Equity: An AAN Position Statement. Neurology. 2026;106(5):e214687. doi:
info_outline
A Roadmap to Neurological Health Equity - Part 1
Neurology Minute
In the first part of this series, Dr. Tesha Monteith and Dr. Nimish A. Mohile discuss what the roadmap is and how it is intended to benefit practicing neurologists. Show citation: Patel PB, Hamilton RH, Budhu JA, et al. A Roadmap to Neurologic Health Equity: An AAN Position Statement. Neurology. 2026;106(5):e214687. doi:
info_outline
Periprocedural Brain Health
Neurology Minute
Dr. Greg Cooper and Dr. Sara Hassani discuss periprocedural brain health and call on neurologists to engage in multidisciplinary efforts to improve periprocedural outcomes. Show citation: Hassani S, Gorelick PB. Periprocedural Brain Health: The Scope of the Problem and the Neurologist's Role. Neurology. 2025;105(12):e214427. doi: Show transcript: Dr. Greg Cooper: Hi, this is Greg Cooper. I just finished interviewing Sara Hassani for this week's Neurology Podcast. For today's Neurology minutes, Sara, I'm hoping you can tell us the main points of your paper. Dr. Sara...
info_outline
Neurological Sequelae After Ebola Virus Disease in Children in Liberia
Neurology Minute
Dr. Paul Crane and Dr. Hanalise Huff discuss neurological and neurocognitive sequelae in pediatric survivors of the 2015 Ebola outbreak in Liberia. Show citation: Huff HV, Van Ryn C, Reilly C, et al. Neurologic Sequelae After Ebola Virus Disease in Children in Liberia: An Observational Study. Neurology. 2026;106(1):e214450. doi:
info_outlineIn part two of this series, Dr. Justin Abbatemarco, Dr. Marjo S. van der Knaap, and Romy J. van Voorst discuss the patient management card and how patients should use it.
Show citation:
and Clinical Management of Vanishing White Matter. Neurology. 2025;105(11):e214320. doi:10.1212/WNL.0000000000214320
Show transcript:
Dr. Justin Abbatemarco:
Hello and welcome back. This is Justin Abbatemarco here with Romy J. van Voorst and Dr. Marjo S. van der Knaap. After discussing her article, Published Neurology Consensus Base Expert Recommendation for Diagnosis and Clinical Management of Vanishing White Matter Disease. Romy, I really want to talk with you about the patient management card. What inspired you to create that in this publication, and how should patients use that?
Romy J. van Voorst:
So what the main motivation was of the study was actually a previous study that we did before. And in this study, we looked at the impact of any short matter on unaffected family members. And we found out that actually many family members encountered clinicians that were unfamiliar with its disease or disease-specific management. And during interviews, we saw that there was an urgent need for moral harmonization of care and also symptom management because families felt like they are left alone with just their child and no guidance on how to go further. And we wrote these recommendations to help families better understand the diagnostic and care process so they can also participate in informed decision-making. So they can understand what kind of preventive measures they can take and whether or not this interferes, for example, with quality of life goals. So there are a lot of different recommendations families can take home with.
Dr. Justin Abbatemarco:
Marjo, anything else you want to add there?
Dr. Marjo S. van der Knaap:
Yeah, I think the management card also helps because they have a physical card when they go to consultation or to emergency room that they can hand over. It's an official publication. It's developed by the Finishing WebMetter Expert Consortium in combination with other experts in combination with patient advocates and representatives. And so it's really a sort of a guidance that cannot be denied. So it has some authority to it.
Dr. Justin Abbatemarco:
But I think it's a theme that applies to many neurological diseases, and addressing that. You do it really practically. And I agree, giving something more tangible for patients to present, especially to non-neurologists to help them give some guidance. It's an idea that we need to think about in clinic all the time on how we're interacting and supporting caregivers and when they're interfacing with the medical community at large. So I love what you guys have done here and to make us think about this more broadly. Thanks again for all your time and your work on this topic.
Dr. Marjo S. van der Knaap:
Thank you for having us.